These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 38427255)
1. Promises of Lipid-Based Nanocarriers for Delivery of Dimethyl Fumarate to Multiple Sclerosis Brain. Subhash S; Chaurawal N; Raza K Methods Mol Biol; 2024; 2761():457-475. PubMed ID: 38427255 [TBL] [Abstract][Full Text] [Related]
2. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis. Traub J; Traffehn S; Ochs J; Häusser-Kinzel S; Stephan S; Scannevin R; Brück W; Metz I; Weber MS Brain Pathol; 2019 Sep; 29(5):640-657. PubMed ID: 30706542 [TBL] [Abstract][Full Text] [Related]
3. A cell-mimicking platelet-based drug delivery system as a potential carrier of dimethyl fumarate for multiple sclerosis. Mehdi-Alamdarlou S; Ahmadi F; Azadi A; Shahbazi MA; Heidari R; Ashrafi H Int J Pharm; 2022 Sep; 625():122084. PubMed ID: 35944590 [TBL] [Abstract][Full Text] [Related]
4. Preclinical Explorative Assessment of Dimethyl Fumarate-Based Biocompatible Nanolipoidal Carriers for the Management of Multiple Sclerosis. Kumar P; Sharma G; Gupta V; Kaur R; Thakur K; Malik R; Kumar A; Kaushal N; Raza K ACS Chem Neurosci; 2018 May; 9(5):1152-1158. PubMed ID: 29357233 [TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Montes Diaz G; Hupperts R; Fraussen J; Somers V Autoimmun Rev; 2018 Dec; 17(12):1240-1250. PubMed ID: 30316988 [TBL] [Abstract][Full Text] [Related]
6. Enhanced Brain Delivery of Dimethyl Fumarate Employing Tocopherol-Acetate-Based Nanolipidic Carriers: Evidence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies. Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K ACS Chem Neurosci; 2017 Apr; 8(4):860-865. PubMed ID: 27983793 [TBL] [Abstract][Full Text] [Related]
7. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248 [TBL] [Abstract][Full Text] [Related]
8. Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. Balasa R; Barcutean L; Mosora O; Manu D Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445097 [TBL] [Abstract][Full Text] [Related]
9. [Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis]. Alifirova VM; Boiko AN; Vlasov YV; Davydovskaya MV; Zakharova MN; Malkova NA; Popova EV; Sivertseva SA; Spirin NN; Khachanova NV; Shmidt ТЕ Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(1):97-102. PubMed ID: 28252608 [TBL] [Abstract][Full Text] [Related]
10. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis. Smith MD; Calabresi PA; Bhargava P Eur J Immunol; 2018 Feb; 48(2):380-383. PubMed ID: 29108094 [TBL] [Abstract][Full Text] [Related]
11. Stearic acid based, systematically designed oral lipid nanoparticles for enhanced brain delivery of dimethyl fumarate. Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K Nanomedicine (Lond); 2017 Dec; 12(23):2607-2621. PubMed ID: 29094640 [TBL] [Abstract][Full Text] [Related]
12. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis. Yadav SK; Soin D; Ito K; Dhib-Jalbut S J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593 [TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
14. Vitamin-Derived Nanolipoidal Carriers for Brain Delivery of Dimethyl Fumarate: A Novel Approach with Preclinical Evidence. Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K ACS Chem Neurosci; 2017 Jun; 8(6):1390-1396. PubMed ID: 28157295 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of preventive treatment with dimethyl fumarate-loaded solid lipid nanoparticles and oral dimethyl fumarate in a mouse model of multiple sclerosis. Bevilacqua Rolfsen Ferreira da Silva G; Pereira das Neves S; Roque Oliveira SC; Marques F; Gomes de Oliveira A; de Lima Leite F; Cerqueira JJ J Autoimmun; 2022 Oct; 132():102893. PubMed ID: 36029715 [TBL] [Abstract][Full Text] [Related]
16. Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis. Guerriero C; Puliatti G; Di Marino T; Tata AM Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408975 [TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison. Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of three newly registered drugs for multiple sclerosis treatment. Kasarełło K; Cudnoch-Jędrzejewska A; Członkowski A; Mirowska-Guzel D Pharmacol Rep; 2017 Aug; 69(4):702-708. PubMed ID: 28550802 [TBL] [Abstract][Full Text] [Related]